Facts

  • Product: PseudoXa
  • Sector: Biotech
  • Founded: 2016
  • Amount invested: € 300,000
  • Status: Follow-up financing secured

VarmX

PseudoXa lowers the risk of death when using anticoagulants.

VarmX’s leading product in development, PseudoXa, can be used to stop acute bleeding in patients who use blood thinners (anticoagulants). The drug consists of a modified natural coagulation factor that can immediately restore blood clotting in patients taking anticoagulants. This avoids serious consequences of bleeding, such as permanent disability or even death.

Want to know more?

Please contact the investment manager.

Hans Dreijklufft

Hans Dreijklufft

Fund Manager

(UNIIQ)

© Copyright - UNIIQ
Secret Link